CAJ | 학술논문

该研究分析了EGFR或EGFR vⅢ过表达是恶性脑胶质瘤的生物标志特征之一。总结得出结论：EGFR抑制剂之一的厄洛替尼有望成为新的治疗方法。有必要对耐药机制进一步研究，对联合药物方案、药物使用先后顺序、剂量进行尝试，以获得更佳疗效。
해연구분석료EGFR혹EGFR vⅢ과표체시악성뇌효질류적생물표지특정지일。총결득출결론：EGFR억제제지일적액락체니유망성위신적치료방법。유필요대내약궤제진일보연구，대연합약물방안、약물사용선후순서、제량진행상시，이획득경가료효。
This paper analyzes the over-expression of epidermal growth factor receptor (EGFR) or EGFR vⅢis one of the major biological characteristics of malignant glioma and summarizes that erlotinib, one of the EGFR inhibitors, is expected to be a new treatment method. In order to obtain a better therapeutic effect, it is necessary to further study the mechanism of drug resistance, and do experiments on combined drug solution, use sequence and dose of drugs.